Cancer Center Support Grant

癌症中心支持补助金

• 批准号: 10514660
• 负责人: RAPHAEL E. POLLOCK
• 金额: $ 10.75万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-12 至 2025-11-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10514660
• 关键词: Address; Appalachian Region; Attention; Basic Science; Breast; Cancer Biology; Cancer Burden; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Research Project; Cancer Survivorship; Catchment Area; Chemoprevention; Clinical Research; Clinical Trials; Colorectal; Community Networks; Community Outreach; Comprehensive Cancer Center; Descriptor; Doctor of Philosophy; Education and Outreach; Endometrial; Engineering; Etiology; FDA approved; Faculty; Fostering; Funding; Growth; Hematopoietic Neoplasms; Human Papilloma Virus Vaccination; Immunooncology; Intervention; Investments; Journals; Leadership; Lesbian Gay Bisexual Transgender Queer; Longevity; Lung; Malignant Neoplasms; Malignant neoplasm of cervix uteri; Manuscripts; Mission; Molecular Biology; Molecular Carcinogenesis; Morbidity - disease rate; Multicultural Education; Obesity; Ohio; Oncology; Patients; Peer Review; Pharmaceutical Preparations; Policies; Population; Population Research; Population Sciences; Prevention; Prostate; Public Health; Publications; Publishing; Research; Resource Sharing; Resources; Rural; Scanning; Scientist; Screening for cancer; Strategic Planning; Therapeutic Trials; Thyroid Gland; Tobacco use; Training; Translating; Translational Research; Underserved Population; Universities; University resources; Vision; anticancer research; cancer genetics; cancer prevention; cancer research center director; clinical development; community engagement; ethnic minority; innovation; leukemia; member; mortality; next generation; outreach; preclinical development; programs; racial and ethnic; recruit; screening; survivorship; translational genomics; translational therapeutics

PROJECT SUMMARY – OVERALL The Ohio State University Comprehensive Cancer Center (OSUCCC) is in its 44th year as an NCI-designated comprehensive cancer center, having received an “exceptional” overall merit descriptor in its last two reviews in 2010 and 2015, and is requesting continued federal support for the next five years. The OSUCCC mission remains to reduce cancer morbidity and mortality through basic, population, translational and clinical research. Through thoughtful strategic planning, attention to the cancer burden in the catchment area (the state of Ohio), effective organizational capabilities and targeted investment, the Director and his Senior Leadership team will enable the OSUCCC to advance collaborative cancer research with local, national and global partners on initiatives of the highest priority to the OSUCCC. The 293 full and introductory members are currently served by 16 full and two developing shared resources and are distributed among our five Research Programs: Cancer Biology (formerly Molecular Biology and Cancer Genetics), Cancer Control, Leukemia Research, Molecular Carcinogenesis and Chemoprevention and Translational Therapeutics. The OSUCCC fosters collaborative basic research and implements strategies that advance and translate early discovery into clinical and population-based research and addresses the needs of our catchment area through research, engagement and outreach, from etiology through prevention, treatment and survivorship regarding the major cancers afflicting our catchment area population. The OSUCCC trains the next generation of cancer-focused scientists and clinicians through new and established programs focused on integrating training for collaborative research efforts. Under the leadership of a new Director, Raphael Pollock, MD, PhD, The OSUCCC supports innovative research efforts within four strategic planning priorities: immuno-oncology, cancer engineering, translational genomics and cancer prevention and survivorship. Since the last CCSG competitive renewal, the OSUCCC has shown significant growth demonstrated by: 1) the recruitment of 108 basic, population, and translational science faculty who are OSUCCC members; 2) the addition of 94,647 ft2 research and administrative space under the full control of the OSUCCC Director; 3) a 16% increase in direct cancer-related funding to $75.4M, with $44.3M coming from the NCI; 4) accrual of 14,996 patients to interventional clinical trials (5,648 accruals to therapeutic trials); 5) increased collaborative and impactful research demonstrated by 3,477 peer-reviewed publications in which 74% of manuscripts are multi-institutional and 85% are collaborative (i.e., inter-, intra-programmatic or multi- institutional); 497 are published in journals with an impact factor >10; 6) the addition of two new shared resources at an institutional investment of $1.3M; and 7) preclinical and clinical development of an FDA approved drug which has changed the treatment for CLL and other blood cancers. With new recruits and strong institutional and philanthropic support in place, the OSUCCC is building upon the momentum and poised in the next five years to take significant steps toward achieving our mission and our broad vision of living in a cancer-free world.

项目概要——总体 俄亥俄州立大学综合癌症中心 (OSUCCC) 已进入 NCI 指定的第 44 个年头 综合癌症中心，在最近两次审查中获得了“特殊”的总体评价描述符 2010 年和 2015 年，并请求联邦政府在未来五年继续提供支持。 OSUCCC 使命 仍然是通过基础、人口、转化和临床研究来降低癌症发病率和死亡率。 通过深思熟虑的战略规划，关注流域（俄亥俄州）的癌症负担， 有效的组织能力和有针对性的投资，董事及其高级领导团队将 使 OSUCCC 能够与地方、国家和全球合作伙伴推进癌症合作研究 OSUCCC 的最高优先级倡议。 293 名正式会员和介绍会员目前由 16 个完整资源和两个正在开发的共享资源，分布在我们的五个研究项目中： 癌症 生物学（原分子生物学和癌症遗传学）、癌症控制、白血病研究、分子 癌发生、化学预防和转化治疗。 OSUCCC 促进协作基础 研究并实施促进早期发现并将其转化为临床和基于人群的策略 通过研究、参与和外展来研究并满足我们流域的需求， 通过预防、治疗和生存来了解困扰我们流域的主要癌症的病因学 地区人口。 OSUCCC 通过以下方式培训下一代以癌症为重点的科学家和临床医生 新的和既定的计划侧重于整合协作研究工作的培训。下 OSUCCC 新任主任 Raphael Pollock 医学博士、哲学博士的领导支持创新研究工作 四个战略规划重点：免疫肿瘤学、癌症工程、转化基因组学和 癌症预防和生存。自上次 CCSG 竞争性更新以来，OSUCCC 已表现出 显着增长体现在：1) 招聘了 108 名基础科学、人口科学和转化科学教师 谁是 OSUCCC 会员； 2) 新增 94,647 平方英尺的完全控制下的研究和行政空间 OSUCCC 主任； 3) 与癌症相关的直接资金增加 16%，达到 7540 万美元，其中 4430 万美元即将到位 来自国家癌症研究所； 4) 介入临床试验累计 14,996 名患者（治疗试验累计 5,648 名患者）； 5） 3,477 份同行评审出版物证明了协作性和有影响力的研究有所增加，其中 74% 的手稿是多机构的，并且 85% 是协作的（即项目间、项目内或多方合作） 机构）； 497篇发表在影响因子>10的期刊上； 6）新增两个共享资源 机构投资 130 万美元； 7) FDA批准药物的临床前和临床开发 这改变了 CLL 和其他血癌的治疗方法。凭借新员工和强大的机构 以及慈善支持到位，OSUCCC 正在乘势而上，并在未来五年内做好准备 多年来，我们采取重大步骤，实现我们的使命和生活在无癌症世界的广阔愿景。